Strategies for developing and commercializing nanobio drugs, diagnostics and devices
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2007 |
|---|---|
| Erschienen: |
2007 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 2(2007), 2 vom: 01. Apr., Seite 137-41 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bunger, Mark [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 18.09.2007 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM172284643 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM172284643 | ||
| 003 | DE-627 | ||
| 005 | 20231223131452.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2007 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0574.xml |
| 035 | |a (DE-627)NLM172284643 | ||
| 035 | |a (NLM)17716115 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bunger, Mark |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Strategies for developing and commercializing nanobio drugs, diagnostics and devices |
| 264 | 1 | |c 2007 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.09.2007 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 2(2007), 2 vom: 01. Apr., Seite 137-41 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2007 |g number:2 |g day:01 |g month:04 |g pages:137-41 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2007 |e 2 |b 01 |c 04 |h 137-41 | ||